Update! Mixed results!
$ALX Oncology(ALXO.US$ ALX Oncology Reports Clinical Data From Ongoing Phase 1/2 Investigator-Sponsored Trial Of Evorpacept In Combination With R2 In Patients With Indolent And Aggressive R/R B-NHL
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well tolerated, and there were no dose-limiting toxicities. Patients with indolent R/R B-NHL (n=18) had a best ORR of 94% and a CRR of 83%. The median duration of response was not reached. "While standard frontline treatments have shown benefit in the indolent B-NHL setting, many patients are likely to see their disease progress after initial treatment," said Paolo Strati, M.D., the trial's lead investigator and Assistant Professor of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center.
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well tolerated, and there were no dose-limiting toxicities. Patients with indolent R/R B-NHL (n=18) had a best ORR of 94% and a CRR of 83%. The median duration of response was not reached. "While standard frontline treatments have shown benefit in the indolent B-NHL setting, many patients are likely to see their disease progress after initial treatment," said Paolo Strati, M.D., the trial's lead investigator and Assistant Professor of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
